ISSN: 2381-8727

炎症、がん、統合療法に関する国際ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Gemcitabine and Triapine Co-Delivery Using Calcium Carbonate Nanoparticles for the Treatment of Chemo-resistant Pancreatic Cancer

Tiaqing Li

Chemotherapy is the primary component of the systemic treatment strategy for pancreatic cancer, which is a fatal disease. However, patients with pancreatic cancer still have a very poor overall prognosis and a low survival rate. Gemcitabine (GEM) is a chemotherapeutic agent that is frequently used to treat pancreatic cancer. However, the primary obstacle remains GEM chemoresistance. To address the issue of Triapine's poor solubility and suppress the GEM resistance of pancreatic cancer cells (PANC-1/GEM), we prepared calcium carbonate nanoparticles (CaCO3 NPs) loaded with a nucleotide reductase inhibitor (Triapine). Using both 2D PANC-1/GEM cells and 3D tumor spheroids, CaCO3-GEM-Triapine NPs nano-formulations inhibited cancer cell proliferation, migration, and resistance to GEM, enhancing the therapeutic effect of GEM-based chemotherapy. According to the findings of the study, CaCO3 NPs containing GEM and Triapine may be an efficient treatment option for overcoming drug resistance in pancreatic cancer.